The historical rank and industry rank for CRISPR Therapeutics AG's Gross Margin % or its related term are showing as below:
CRSP'
s Gross Margin % Range Over the Past 10 Years
Min: -25186.7 Med: -89.98 Max: 88.92
Current: -20092
During the past 12 years, the highestGross Margin % of CRISPR Therapeutics AG was 88.92%. The lowest was -25186.70%. And the median was -89.98%.
CRSP's Gross Margin % is ranked worse than 99.73% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs CRSP: -20092.00
CRISPR Therapeutics AG had a gross margin of -4,494.90% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CRISPR Therapeutics AG was 0.00% per year.
CRISPR Therapeutics AG (NAS:CRSP) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CRISPR Therapeutics AG had a gross margin of -4,494.90% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CRISPR Therapeutics AG Gross Margin % Related Terms
CRISPR Therapeutics AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRSP vs CGON, XENE, DNTH: Gross Margin % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CRISPR Therapeutics AG (CRSP) has a Gross Margin % of -4,494.90% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #734 out of 736 companies in the Biotechnology industry, placing it in the top 99.7%.
Is CRISPR Therapeutics AG's Gross Margin % too high?
CRISPR Therapeutics AG's current Gross Margin % is -4,494.90%. Based on the distribution chart, CRISPR Therapeutics AG ranks #734 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Gross Margin % compare to CGON and XENE?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #734 out of 736 companies for Gross Margin %. This places CRISPR Therapeutics AG in the lower half of its industry. The industry median Gross Margin % is 60.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CRISPR Therapeutics AG and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Gross Margin % is -4,494.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.44, compared to a current price of $54.92 — trading 2150.8% above its estimated fair value. The current Gross Margin % is -4,494.90%. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Gross Margin % is -4,494.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $54.92 is trading 2150.8% above its estimated GF Value™ of $2.44.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
Gross Margin %: -4,494.90%
GF Value™: $2.44 vs. price of $54.92 (2150.8% above fair value)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 
